Dublin, OH (June 11, 2013) – Dr. Nancy Sawtell, a professor, and researcher at Cincinnati Children’s Hospital Medical Center, will be using technology developed by Biosortia Pharmaceuticals of Dublin, Ohio in collaboration to potentially discover new biologically active natural products for the treatment of infectious diseases. The drug discovery research is focused on the evaluation of Biosortia’s unique fractions and compounds for the treatment of infectious diseases. With expertise in molecular mechanisms of herpesvirus latency and reactivation, viral persistence, and pathogenesis, Dr. Sawtell will lend valuable experience to Biosortia’s drug discovery efforts.

Biosortia Pharmaceuticals will provide its unique compounds and fractions that are produced by a consortium of microscopic organisms in the natural aquatic environment, a rich source of metabolically active organisms. The consortium includes microalgae, bacteria, and fungi and their secondary metabolites, a complex living consortium developed for survival in a highly competitive environment. Dr. Sawtell, in collaboration with Biosortia’s Chief Science Officer, Dr. Guy Carter, will investigate the unique chemistry for activity against infectious disease targets. Biosortia would be responsible for commercializing these new compounds to various pharmaceutical companies for further development into new drugs.

Biosortia’s Chief Scientific Officer, Dr. Guy Carter stated: “Biosortia collaborates with the best researchers in our strategic therapy areas. We see great potential in this drug discovery project.”

###

About Biosortia Pharmaceuticals – Biosortia Pharmaceuticals Biosortia Pharmaceuticals is a division of Algaeventure Systems (AVS). Biosortia has a proven and unique ability to obtain unculturable aquatic microorganism consortia from the natural environment in unprecedented quantities that allows its research team to perform a direct study of vast quantities of new natural products. Biosortia is actively engaging drug research and development organizations to explore the vast opportunity of unculturable microorganisms for potential therapeutic agents, and other novel compounds of value in biotechnology fields.